Previous Article | Next Article ![]()
Journal of Virology, May 2009, p. 4557-4564, Vol. 83, No. 9
0022-538X/09/$08.00+0 doi:10.1128/JVI.00026-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Microbiology and Immunology, New York State College of Veterinary Medicine, Cornell University, Ithaca, New York 14853
Received 6 January 2009/ Accepted 10 February 2009
|
|
|---|
|
|
|---|
Incorporation of the portal into the capsid is mediated by its interaction with amino acids 143 to 151 of ICP35, the major component of the internal shell of the two-shelled capsid (9, 18, 28). In the absence of this scaffold protein sequence, the portal protein fails to interact efficiently with ICP35 in vitro and is not incorporated into the capsids.
Like those of all herpesviruses, the HSV type 1 (HSV-1) portal protein contains a potential leucine zipper between amino acids 422 and 443, in which three invariant leucines are separated by 6 amino acids, thus potentially placing them on one side of an
-helix (data not shown). Because such motifs have been implicated in a number of protein-protein interactions, and protein interactions represent critical functions of the portal vertex, this motif has garnered experimental interest. Specifically, deletion of codons 409 to 473, or changing leucines at positions 429 and 436 to glutamic acid, reduced incorporation of the portal into capsids and precluded normal formation of portal rings in vitro (14).
One goal of the current work was to determine how the terminase docks with the capsid. The portal protein pUL6 coimmunoprecipitates with both pUL15 and pUL28, suggesting these proteins interact in vivo (27). This hypothesis is also supported by observations that pUL6 (i) coimmunoprecipitates with either pUL15 or pUL28 overexpressed in insect cells and (ii) can alter the localization of pUL28 and pUL15 in mammalian cells when these proteins are coexpressed with pUL6 in the absence of other viral proteins (24).
Because our previous observations (27) indicated that the coimmunoprecipitation of pUL15 and pUL6 from infected cells is more robust than that of pUL28 and pUL6, we focused primarily on the pUL6/pUL15 interaction in the current study. The data indicated that although codons 422 to 443 of UL6 were dispensable for interaction with scaffold protein and incorporation of the portal into the capsid, they were critical for (i) DNA cleavage and packaging, (ii) interaction between pUL15 and pUL6 in lysates of both uninfected and infected cells, (iii) coimmunoprecipitation with transiently expressed pUL6 and pUL28, and (iv) association of normal levels of pUL15, pUL28, and pUL33 with the capsid. These data suggest that docking of the terminase with the capsid involves interactions between the portal protein and both the UL15-encoded and pUL28-encoded terminase subunits and shed new light on the importance of the putative leucine zipper of the portal in HSV DNA packaging.
|
|
|---|
Plasmids. The full-length UL15 gene with a hemagglutinin (HA) tag inserted in-frame at the C terminus was amplified by PCR and cloned into the HindIII and EcoRV sites located in the multiple cloning site of expression vector pCDNA3. The resulting plasmid was designated pJB517. Plasmid pJB437 containing the entire UL6 coding sequence was described previously (27). UL6 genes fused at the 5' or 3' end to DNA encoding a Flag epitopic tag were amplified by PCR and cloned into the BamHI and EcoRI sites located in the multiple cloning site of expression vector pcDNA3. The resulting constructs were designated pJB444 and pJB445, respectively. To delete codons 422 to 443 from UL6, encoding a putative leucine zipper, two-step PCR was performed. The resultant PCR amplicons were cloned into pcDNA3 at the BamHI and EcoRI sites, and the resulting plasmid was designated pJB454. Similarly, amino-terminally truncated UL6 (as shown in the diagram of Fig. 1) was amplified by PCR, using pJB437 or pJB454 as a template. PCR products were cloned into the BamHI and EcoRI sites of pCDNA3, and the resulting plasmids were designated pJB507 and pJB645, respectively. To construct pJB456 and pJB557, plasmids pJB347 and pJB454 were digested with BamHI and NotI, and the inserts were purified and cloned into pcDNA5/FRT at the BamHI and NotI sites. All plasmid constructs were confirmed by immunoblotting after transient expression in mammalian cells and DNA sequencing by the Cornell University DNA sequencing and genotyping core facility (data not shown). To replace the sequence for the putative leucine zipper of pUL6 with the amino acid sequence of the GCN4 leucine zipper (LEDKVEELLSKNYHLENEVARL), two-step PCR was performed, the final PCR amplicons were cloned into pCDNA3 at the BamHI and EcoRI sites, and the resulting plasmid was designated pJB584.
![]() View larger version (14K): [in a new window] |
FIG. 1. (A) Schematic diagram of the full-length pUL15 (top line), pUL6 (second line from top), and UL6 mutant (other lines) proteins. The designation of the plasmid and genotype are indicated on the right. Numbers in the rightmost column followed by aa indicate the amino acids present in the corresponding construct. (B) Schematic diagram of the UL6 gene of the deletion mutant virus vJB10 or its corresponding genetically restored virus vJB10R.
|
Construction of complementing cell lines. CV6 and CV6M cell lines were made by using the Flp-In-CV1 system (Invitrogen) according to the manufacturer's protocol and as described previously (28). Briefly, either pJB456 or pJB557 was cotransfected with plasmid pOG44, encoding Flp recombinase under the constitutive cytomegalovirus promoter/enhancer, into an engineered cell line (Flp-In-CV1). Correct insertion of the shuttle vector caused simultaneous loss of Zeocin resistance and gain of hygromycin resistance. After recombination, cells resistant to hygromycin were selected by growth in DMEM supplemented with 10% newborn bovine serum and 200 µg/ml hygromycin B.
Construction of recombinant viruses. Production and characterization of a bacterial artificial chromosome (BAC) containing the entire HSV-1(F) genome was described previously (20). Recombinant viruses were constructed by en passant mutagenesis, a two-step Red-mediated recombinant system described by Tischer et al. (22). The details of the procedure and their use in construction of recombinant HSV-1 genomes were also described previously (27). The primers for the production of a PCR amplicon for eventual deletion of codons 422 to 443 from the UL6 gene in the HSV-1(F)-containing BAC were as follows: forward, TTCCGCACGGCCGTGGTTAACAACATCAACGGCGTGGCGACCCAATTGCAGGAGTAGGGATAACAGGGTAATCGATTT; reverse, CCGGAGCTCGCGGTCGCGCTCCTGCAATTGGGTCGCCACGCCGTTGATGTTGTTGCCAGTGTTACAACCAATTAACC.
The expected mutation in the BAC DNA was confirmed by DNA sequencing, and the resulting recombinant BAC was designated bJB10. Purified bJB10 BAC DNA was cotransfected with a Cre expression plasmid (see above) into CV6 cells expressing pUL6. The presence of viable recombinant virus was confirmed by plaque formation on complementing CV6 cells, and the resulting virus was subjected to two further rounds of plaque purification. The genotype of the recombinant virus, designated vJB10, was confirmed by PCR and DNA sequencing, whereas the viral phenotype was characterized as described below in Results. To repair the mutated UL6 gene, rabbit skin cells were cotransfected with vJB10 viral DNA and linearized pRB132, which contains the gene fragment from bases 11820 to 21655 of the HSV-1 genome, according to the numbering scheme of McGeoch et al. (13). The virus arising from homologous recombination was able to form plaques on rabbit skin cells and was designated vJB10R. The genotype of vJB10R was confirmed by DNA sequencing, immunoblotting, and Southern blot analyses (data not shown).
Immunoprecipitation and immunoblotting. These procedures were performed essentially as described previously (23, 24). Briefly, CV1 cells were either transfected with expression plasmids containing UL15, UL28, and UL6 or its derivatives or infected with wild-type or recombinant viruses. At 24 h after transfection or 18 h after infection, the cells were washed with cold phosphate-buffered saline (PBS) and lysed in cold radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, and 1x protease inhibitor cocktail (Roche). Rabbit anti-HA polyclonal antibody (HA-probe, Y-11, SC-805 diluted 1:200; Santa Cruz Biotechnology) was used for pUL15 immunoprecipitation, whereas pUL6-specific rabbit polyclonal serum (diluted 1:100) was used to immunoprecipitate pUL6. Anti-ICP35 monoclonal antibodies (MCA 406; AbD Serotec) were used for immunoprecipitation at a dilution of 1:200. pUL28-specific rabbit polyclonal antisera were diluted 1:100 to immunoprecipitate pUL28. Immune complexes, RIPA buffer-solubilized clarified lysates, total lysates solubilized in 1% sodium dodecyl sulfate (SDS) and beta-mercaptoethanol, and in some experiments, SDS-denatured purified B capsids were separated on SDS-polyacrylamide gels and transferred to nitrocellulose membranes for immunoblotting.
Immunoblots were probed with anti-HA antibodies diluted 1:1,000, anti-pUL15C diluted 1:1,000, anti-pUL28 diluted 1:1,000, anti-pUL33 diluted 1:400, anti-ICP35 (MCA 406; AbD Serotec) diluted 1:2,000, anti-VP5 (HA018-100; Virusys Corporation) diluted 1:1,000, and/or anti-pUL6 polyclonal antiserum diluted 1:1,000. The bound immunoglobulins were revealed by reaction with horseradish peroxidase-conjugated anti-immunoglobulins and visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech). Where applicable, the image intensities of specific bands on the immunoblots were quantified with an LAS-3000 mini Fujifilm imaging system (Fuji Photo Film Co., Ltd.).
Capsid purification. CV1 cell monolayers from two 850-cm2 roller bottles were infected with either HSV-1(F) or mutant viruses at a multiplicity of infection (MOI) of 5 PFU/cell. The cells were harvested 20 hours later and washed with cold PBS. Cell pellets were suspended in 25 ml of lysis buffer (1 mM dithiothreitol, 1 mM EDTA, 20 mM Tris [pH 7.6], 500 mM NaCl, 1% Triton X-100, and protease inhibitor), sonicated briefly, and precleared by spinning at 10,000 x g for 15 min. The precleared lysates were pelleted through a 5-ml 35% sucrose cushion in TNE buffer (20 mM Tris-HCl [pH 7.6], 500 mM NaCl, 1 mM EDTA), in an SW28 ultracentrifuge tube at 24,000 rpm for 1 h. The pellets were resuspended in TNE buffer and applied to 20% to 50% sucrose gradients in SW41 ultracentrifuge tubes followed by centrifugation at 24,500 rpm for 1 h. After centrifugation, the light-refracting B capsid band was removed with a Pasteur pipette. Purity of the capsid preparations was evaluated by transmission electron microscopy and negative staining (data not shown).
Southern blotting. Approximately 2 x 106 CV1 cells were infected with HSV-1(F), vJB10, or vJB10R. At 18 h postinfection, viral DNA was extracted, digested with BamHI, separated on 0.8% agarose gels, and transferred to nylon membranes as described previously (24). The bound DNA was UV cross-linked to the membrane and hybridized with a denatured [32P]dCTP-labeled BamHI P fragment of HSV-1(F) DNA at 42°C for 24 h. The membrane was washed twice with 1x SSC (0.15 M NaCl plus 0.015 M sodium citrate) at 42°C for 15 min each time and once with 0.1x SSC-0.1% SDS for 1 h at 64°C and then fluorographed by exposure to X-ray film at –80°C in the presence of intensifying screens.
Virus replication assay. Approximately 2 x 106 cells in 25-cm2 flasks were infected with the viruses indicated in Table 1 at an MOI of 0.1 PFU/cell. After adsorption for 2 hours at 37°C with shaking, the inoculates were removed, and the cells were washed with CBS buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl [pH 3.0]) to remove residual infectivity. The cells were then washed with PBS once and overlaid with 5 ml of DMEM supplemented with 5% newborn calf serum. Twenty-four hours after infection, virus was harvested by three cycles of freezing and thawing, and the infectious yields were determined by plaque assay on the cell monolayers indicated in Table 1.
|
View this table: [in a new window] |
TABLE 1. Virus replication assay
|
|
|
|---|
As shown in Fig. 2, lane 2, pUL15 and pUL6 were expressed to readily detectable levels in lysates of the transfected cells, but not in mock-transfected cells. Moreover, the HA-specific antibody readily immunoprecipitated HA-tagged pUL15, and the pUL6-specific antibody successfully immunoprecipitated pUL6. Most importantly for the purposes of this report, material immunoprecipitated with the HA-specific antibody also contained pUL6, and reaction with the pUL6 antibody caused coimmunoprecipitation of pUL15. We conclude that transiently expressed pUL15 and pUL6 interact as assessed by immunoprecipitation.
![]() View larger version (59K): [in a new window] |
FIG. 2. Insertions of Flag epitopic tags at the N or C terminus of pUL6 preclude interaction with transiently expressed pUL15. CV1 cells (2 x 106) were cotransfected with plasmids encoding pUL15-HA and wild-type UL6 (lane 2) or Flag-tagged pUL6 (lanes 3 and 4) or were mock transfected (lane 1). Twenty-four hours after transfection, reciprocal coimmunoprecipitation with either anti-pUL6 or anti-HA antibodies was performed. Cell lysates and immunoprecipitated proteins were electrophoretically separated in denaturing 12% polyacrylamide gels and transferred onto a nitrocellulose membrane. The transferred proteins were probed with anti-pUL6 (B, D, and E) or anti-HA (A, C, and F) antibodies. Bound immunoglobulins were revealed by enhanced chemiluminescence. IP, immunoprecipitation with the indicated antibody; IB, immunoblotting with the indicated antibody. The arrows indicate the positions of proteins of interest.
|
![]() View larger version (52K): [in a new window] |
FIG. 3. Only the full-length pUL6 interacts with pUL15 in transiently transfected cells. CV1 cells (2 x 106) were mock transfected (lane 1) or cotransfected with plasmids encoding pUL15-HA and full-length pUL6 (lane 2), N-terminally truncated pUL6 (lane 3), or N-terminally truncated pUL6 lacking the putative leucine zipper (lane 4). Twenty-four hours after transfection, coimmunoprecipitation was performed with anti-pUL6 antibodies. Cell lysates and immunoprecipitated material were separated on 12% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane. The transferred proteins were probed with anti-pUL6 (B and C) or anti-HA (A and D) antibodies. Bound immunoglobulins were revealed by reaction with appropriately conjugated anti-immunoglobulins followed by enhanced chemiluminescence. IP, immunoprecipitation with the indicated antibody; IB, immunoblotting with the indicated antibody. The arrows indicate the positions of proteins of interest.
|
![]() View larger version (38K): [in a new window] |
FIG. 4. The putative leucine zipper of pUL6 of HSV-1(F) is required for pUL6 and pUL15 interaction in the absence of other viral proteins. CV1 cells were cotransfected with plasmids encoding full-length pUL15 with a C-terminal HA tag and wild-type pUL6 (lane 1), pUL6 lacking amino acids 422 to 443 (lane 2), or a pUL6-GCN4 chimera (lane 3) in which codons 422 to 443 of UL6 were replaced with the sequence encoding the GCN4 leucine zipper. Twenty-four hours after transfection, reciprocal coimmunoprecipitations were performed with anti-pUL6 or anti-HA antibodies. Cell lysates and immunoprecipitated proteins were separated on denaturing 12% polyacrylamide gels and transferred to a nitrocellulose membrane. The transferred proteins were probed with anti-pUL6 (B, D, and E) or anti-HA (A, C, and F) antibodies. Bound immunoglobulins were detected as indicated in the legend to Fig. 3. IP, immunoprecipitation; IB, immunoblotting. The arrows indicate the positions of proteins of interest.
|
![]() View larger version (50K): [in a new window] |
FIG. 5. The putative leucine zipper of HSV-1(F) pUL6 is required for interaction with pUL28 in the absence of other viral proteins. Cells were transfected with plasmids encoding full-length pUL28 and wild-type pUL6 (lane 1), pUL6 lacking codons 422 to 443 (lane 2), or pUL6 in which codons 422 to 443 were replaced by a leucine zipper of GCN4 (lane 3). The cells were lysed 24 h later and either immunoblotted with antibodies directed against pUL6 or pUL28 (A and B) or subjected to immunoprecipitation with antibody directed against pUL28. The presence of pUL6 or pUL28 in immunoprecipitated material was determined by immunoblotting (C and D, respectively). IP, antibody used for immunoprecipitation in the corresponding panel; IB, antibody used for immunoblotting in the corresponding panel. The arrows indicate the positions of proteins of interest.
|
To determine the role of pUL6 amino acids 422 to 443 on the pUL6/pUL15 interaction in infected cells, CV1 cells were infected with HSV-1(F) or vJB10, and infected cell lysates were immunoprecipitated with pUL6- or pUL15-specific antisera. The presence of either pUL6 or pUL15 in immunoprecipitated material was then assessed by immunoblotting. As shown in Fig. 6, the absence of codons 422 to 443 did not preclude expression or solubility of pUL6 but abrogated coimmunoprecipitation with pUL15. This was despite the fact that wild-type pUL6 and pUL15 coexpressed in HSV-1(F)-infected cells readily coimmunoprecipitated. We therefore conclude that UL6 codons 422 to 443 are required for interaction with pUL15 in infected cell lysates.
![]() View larger version (58K): [in a new window] |
FIG. 6. The putative leucine zipper of HSV-1(F) pUL6 is required for the interaction between pUL6 and pUL15 in virus-infected cells. CV1 (2 x 106) cells were infected with a UL6 null mutant, leucine zipper deletion virus (vJB10), or HSV-1(F) at an MOI of 5 PFU per cell. Eighteen hours after infection, cells were lysed in RIPA buffer with 1 M NaCl, and immunoprecipitation was performed with anti-pUL6 antibody. Cell lysates and immunoprecipitated proteins were electrophoretically separated on four separate polyacrylamide gels and immunoblotted with anti-pUL15C or pUL6-specific antibodies. Bound immunoglobulins were revealed as indicated in the legend to Fig. 3. The arrows indicate the positions of proteins of interest. Note that the gels were run for different periods of time, accounting for the different migrations of bands in the different panels. IP, antibody used for immunoprecipitation in the corresponding panel; IB, antibody used for immunoblotting in the corresponding panel.
|
![]() View larger version (50K): [in a new window] |
FIG. 7. The virus with mutant UL6 lacking the putative leucine zipper is defective in viral DNA cleavage. Approximately 2 x 106 CV1 cells were infected with 5 PFU per cell of HSV-1(F), vJB10, or vJB10R, which was derived from vJB10 but contains a genetically restored UL6 gene. Viral DNA was extracted about 15 hours after infection, digested with BamHI, transferred to a nylon membrane (0.45 µM), and hybridized with a radiolabeled BamHI P fragment of HSV-1(F) DNA. Bound probe DNA was detected by fluorography.
|
![]() View larger version (58K): [in a new window] |
FIG. 8. Deletion of the putative leucine zipper of pUL6 does not block interaction with the scaffold protein ICP35. CV1 cells were infected with 5 PFU per cell of the UL6 null mutant, leucine zipper deletion virus (vJB10), or HSV-1(F). Eighteen hours after infection, the cells were lysed in RIPA buffer and reacted with ICP35-specific monoclonal antibody. Immunoprecipitated proteins were immunoblotted with anti-pUL6 (A) or anti-ICP35 (B) antibodies. Bound immunoglobulins were revealed by reaction with appropriately conjugated immunoglobulins followed by enhanced chemiluminescence.
|
![]() View larger version (49K): [in a new window] |
FIG. 9. Immunoblot of B capsids probed with pUL15-, pUL6-, pUL33-, pUL28, or VP5-specific antibodies. Approximately 4 x 108 CV1 cells were infected with viruses UL6 null, vJB10, or HSV-1(F) at an MOI of 5 PFU per cell. Twenty hours after infection, capsids were purified, and B capsids were denatured, separated by SDS-polyacrylamide gel electrophoresis, and transferred onto a nitrocellulose membrane, followed by immunoblotting with anti-pUL15C, anti-pUL6, or anti-VP5 antibodies. Bound immunoglobulin was revealed by enhanced chemiluminescence as described in the legend of Fig. 3. The intensity of each band was determined using an LAS-3000 mini Fujifilm imaging system. The intensity of the band on each panel is reported as a percentage of the signal in the lane containing HSV-1(F) proteins and is shown below each band.
|
|
|
|---|
The observations that both pUL15 and pUL28 can interact with pUL6 independently suggest that docking of the terminase with the portal involves interactions between the two larger subunits of the terminase and the portal. This conclusion is consistent with the data of others showing that pUL28 and pUL15 can interact with pUL6 independently (24). Parenthetically, we did not detect an interaction between pUL6 and pUL33 in the absence of other viral proteins as assessed by immunoprecipitation (data not shown).
In the absence of structural data, it is unclear that a leucine zipper is actually encoded by codons 422 to 443 of UL6. Possibly the best arguments for such a motif are the conservation of aligned leucines in a number of herpesvirus portals and the observation that substitution of leucines 429 and 436 with glutamic acids precludes normal portal ring formation and incorporation of the portal into capsids (14). Nevertheless, replacement of the putative leucine zipper with a sequence known to form such motifs in other contexts was insufficient to restore pUL15 or pUL28 binding (Fig. 4 and 5).
Although the structure of pUL6 is unknown, alignment of herpesvirus portal proteins with the solved structures of bacteriophage
29 and SPP1 portals potentially reveals a structurally conserved region consisting of several
-helices (12). The most C-terminal of these helices (helix 6) is predicted at amino acids 406 to 454 of pUL6 by using PSIPRED version 2.6 (6, 11). Helix 6 is a long, kinked
-helix that emanates roughly perpendicularly to the DNA channel, forming an external ridge or wing in the SPP1 portal (12). In the bacteriophage systems studied, this helix is proposed to interact with other portal subunits through a relatively sparse set of hydrogen bonds rather than through a leucine zipper.
The mutations described here and in previous studies are predicted to affect the stability, charge, register, and/or length of helix 6 as follows: (i) deletion of codons 409 to 473 should completely remove the helix, (ii) deletion of codons 422 to 443 should decrease its length by 7 amino acids and truncate and displace a hydrophobic patch by about 140 degrees relative to that of the wild type motif, (iii) replacement of codons 422 to 443 with the GCN4 leucine zipper should maintain the position of the leucines and hydrophobic patch and lengthen the helix by 9 amino acids, and (iv) changing leucines 429 and 436 to glutamic acids should disperse hydrophobic residues, precluding a prominent hydrophobic region.
Normal levels of portal proteins were incorporated into capsids purified from cells infected with vJB10 (Fig. 9) but were less efficiently incorporated into capsids when (i) codons 409 to 473 were deleted or (ii) leucines 429 and 436 were changed to glutamic acids (14). Given that vJB10 preserves a remnant (albeit displaced) of the hydrophobic region of helix 6, the data suggest that hydrophobic interactions are involved in intersubunit interactions within the HSV-1 portal. On the other hand, the failure of GCN4 to restore terminase binding of the deletion in helix 6 argues against the possibility that subunit interactions involve interdigitation of leucines as in a classic leucine zipper.
As might be expected given the structure of other portals, attempts to demonstrate an interaction between pUL6 amino acids 422 to 443 with either pUL6, pUL28, or pUL15 have not been successful (not shown). Taken together, the data support the idea that this region plays an indirect role in portal/terminase interactions, probably by ensuring proper portal morphology.
Our data also suggest that both amino and carboxyl termini of pUL6 are necessary for interaction with pUL15. Specifically, insertion of epitopic tags into the N or C terminus of pUL6 did not preclude protein solubility, expression of the recombinant proteins, or interaction with ICP35 (not shown), but precluded coimmunoprecipitation with pUL15 in transient expression assays. Moreover, deletion of either the N terminus or C terminus of pUL6 precluded coimmunoprecipitation with pUL15. Little is known about the orientation of pUL6 in the capsid other than the fact that epitopes within the C-terminal 298 amino acids of pUL6 are located at the external surface (15, 21, 25). Moreover, the termini are not homologous to bacteriophage portal proteins and so do not provide clues as to function. Thus, it is uncertain if the pUL6 termini interact directly with pUL15 or act to ensure proper conformation of pUL6 and, thereby, promote interaction with pUL15 indirectly.
The large number of UL6 mutations that can preclude the interaction with pUL15 is striking to us, and we speculate that terminase docking is exquisitely dependent on proper conformation of the portal in the capsid. This is supported by the observation that expression of the defective portal protein acts as a dominant negative inhibitor of wild-type virus (Table 1), presumably because optimal portal conformation cannot tolerate defective subunits. Because the terminase with bound DNA may have a choice of a number of potential capsids with which to dock, this structural constraint to at least the pUL15/pUL6 interaction may represent an important assembly checkpoint to ensure efficient viral DNA cleavage and packaging.
These studies were supported by R01 grant GM50741 from the National Institutes of Health.
Published ahead of print on 18 February 2009. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»